http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
원발성 폐암에서 p53 의 발현과 S - Phase Fraction 및 예후와의 관계
정은택(Eun Taik Jeong),양세훈(Sei Hoon Yang),김학렬(Hak Ryul Kim),정병학(Byung Hak Jeong),문형배(Hyung Bae Moon) 대한내과학회 1996 대한내과학회지 Vol.51 No.5
Objectives: The p53 has been implicated in the control of cell cycle, DNA repair and programmed cell death especially, arrest of the cell cycle at G1 phase during DNA damage and repair. It is now widely accepted that mutations of p53 are among the most common changes that occur during malignant progression of diverse types of cancer. Based on this information, it seems reasonable to expect that there may be clinical prognostic significance of p53 changes in primary lung cancer. But its prognostic significance is controversial. Methods: To investigate the role of p53 mutation in lung cancer, we performed immunohistochemical stain of p53 on 57 resected primary non-small cell lung cancer specimens, thereafter, flow cytometric cell cycle analysis was done. And we analyzed the correlation between p53 expression, S-phase fraction and survival. Results: 1) p53 was detected in 70% of total 57 patients (according to histologic type, squamous carcinoma 74%, adenocarcinoma 69%, large Cell carcinoma 33%). p53 was positive in 71% of stage 1, 76% of stage 2, 63% of stage 3a, 67% of stage 3b (statistic insignificance). 2) Using the flow cytometric cell cycle analysis, mean S-phase fraction of p53(+) and (-) group are 21.3 (±7.4)%, 16.5 (±6.4)% (p<0.05) and mean G1 phase fraction of p53(+) and (-) group are 67.9 (±9.8)%, 75.4 (±10.5)% (p<0.05). 3) The median survival time of mt p53(+) and (-) group are 29.3 months, 39.5 months, but this could not reach the statistic significance. Conclusion: p53 was detected in 70% of primary non-small cell lung cancers. The S-phase fraction of p53(+) group was longer than (-) group (p<0.05). But, p53 could not be a prognostic factor.
Flow Cytometer 를 이용한 , 결핵환자의 말초혈액 및 늑막저류액에서의 T - 임파구아형의 변화에 관한 연구
정은택(Eun Taik Jeong),정헌택(Hun Taeg Chung),박경옥(Kyung Ock Park) 대한내과학회 1989 대한내과학회지 Vol.37 No.1
N/A Recently, the development of monoclonal antibodies against human T lymphocytes subsets has allowed the classification of T cell subsets based on functional properties, namely helper/inducer and suppressor/ cytotoxic cells. The importance of a balance between helper and suppressor cells in maintaining immune homeostasis has recently been illustrated and abnormalities in these T cell subsets have been associated with tuberculous diseases. The flow cytometric study was performed to observe the change of the percentage of T-lymphocyte subsets in the peripheral blood of normal controls, pulmonary tuberculosis and tuberculous pleurisy patients, and in the pleural fluid of tuberculous pleurisy patients. The results obtained were as follows: 1) In normal controls, the percentage of T4+ and T8+ and T4+/T8+ ratio in peripheral blood were 43.66±7.91 %, 28.23±3.07% and 1.57±0.38, respectively. 2) In the peripheral blood of pulmonary tuberculosis and tuberculous pleurisy patients, the percentates of T4+ were 39.33±12.10 % and 40.24±8.01%, that of T8+ were 22.26±8.73% and 22.65±8.07% and the T4+/T8+ ratios were 2.06±0.55 and 2.06±0.99. T4 was decreased insignificantly. T8+ was decreased significantly and T4+/T8+ was increased insiginficantly in both groups compared with the normal controls. 3) The tuberculous pleurisy patients showed a significant increase in the percentage of T4+ cells (57.43±9.54 %) and in the T4+/T8+ ratio (3.07±1.27), but no change in the percentage of T8+ cells (20.73±6.00%) in the pleural fluid compared with peripheral blood.
확장기 소세포폐암에서 1차 치료로서 Irinotecan + Cisplatin 복합요법의 임상적 결과
황기은 ( Ki Eun Hwang ),김소영 ( So Young Kim ),정종훈 ( Jong Hoon Jung ),박성훈 ( Seong Hoon Park ),박정현 ( Jung Hyun Park ),김휘정 ( Hwi Jung Kim ),김학렬 ( Hak Ryul Kim ),양세훈 ( Sei Hoon Yang ),정은택 ( Eun Taik Jeong ) 대한결핵 및 호흡기학회 2006 Tuberculosis and Respiratory Diseases Vol.61 No.2
연구배경: Toptisomerase I 억제제인 irinotecan 과 소세포폐암 치료의 근간인 cisplatin의 복합화학용법을 확장기 소세포폐암 환자에게 1차 치료법으로 실시하여 반응률, 생존율 및 부작용을 확인하였다. 방법: 2002년 6월부터 2005년 2월까지 확진된 확장기 소세포폐암 환자 39명에게 irinotecan 60㎎/㎡, 제 1, 8, 15일째 cisplatin 60㎎/㎡ 제1일째에 28일 간격으로 4회 투여하였다. 결과: 반응률은 77%(완전반응 8%), 중앙생존기간은 14.8개월, 1-및 2-년 생존율은 60.9%, 27.6%였으며, 중앙 무진행생존기간은 8.4개월, 6-및 12-개월 무진행생존율은 75.0%, 18.8%였다. WHO grade 3 이상의 부작용은 백혈구 감소증 23%, 설사 26%였으나, 심한 설사때문에 2명은 치료방법을 바꾸었고, 1명은 사망하였다. 결론: Irinotecan과 cisplatin 복합화학요법은 확장기 소세포폐암 환자의 1차 치료법으로 유용하며, 부작용으로서 설사에 대해서는 치명적일수 있으므로 심각한 주의가 요망된다. Background: Irinotecan (topoisomerase I inhibitor) is effective as a monotherapy against small-cell lung cancer(SCLC). Cisplatin is also an important drug against SCLC. A phase II study of irinotecan combined with cisplatin was carried out to evaluate the efficacy and toxicity of this combined regimen as a first line treatment in patients with extensive SCLC. Methods: Thirty-nine patients with previously untreated extensive SCLC were enrolled in this study. Irinotecan 60㎎/㎡ was administered intravenously on days 1, 8 and 15, and in combination with cisplatin 60㎎/㎡ on day 1 and every 28 days thereafter. Four cycles of chemotherapy were given to the patients. Results: The overall response rate was 77% with a complete response (CR) rate of 8%. The median survival time, 1- and 2-year survival rate were 14.8 months, 60.9% and 27.6%, respectively. The median progression free survival time, 6-and 12-month progression free survival rate were 8.4 months, 75% and 18.8%, respectively. The WHO grade 3 or more toxicity encountered were leukopenia (23%), diarrhea (26%). Two patients changed their chemotherapeutic regimen and one patient died from severe diarrhea. Conclusion: The combination of irinotecan and cisplatin is effective as a first line therapy in extensive SCLC is effective, but has severe or fatal diarrhea as toxicity. (Tuberc Respir Dis 2006; 61: 143-149)